

**From:** Smith, Michael (CBER)  
**Sent:** Tuesday, July 27, 2021 10:44 AM  
**To:** Harkins Tull, Elisa <Elisa.HarkinsTull@pfizer.com>; Aghajani Memar, Neda <Neda.AghajaniMemar@pfizer.com>; Devlin, Carmel M <Carmel.Devlin@pfizer.com>  
**Cc:** Naik, Ramachandra <Ramachandra.Naik@fda.hhs.gov>; Gottschalk, Laura <Laura.Gottschalk@fda.hhs.gov>  
**Subject:** RE: [EXTERNAL] RE: STN 125742.0: IR RE assessment of vaccine effectiveness

Elisa,

Sorry, but the below question was inadvertently omitted from the earlier IR. Additionally, the review team has requested a response to this question by Friday, July 30, 2021.

Please calculate the cumulative incidence rates of vaccine and placebo arms at Day 57 and Day 224 and estimate the Risk Difference and Risk Ratio with their 95% CI.

Regards,

Mike

- Please confirm receipt of this e-mail and let us know if you have any questions.

**From:** Harkins Tull, Elisa <[Elisa.HarkinsTull@pfizer.com](mailto:Elisa.HarkinsTull@pfizer.com)>  
**Sent:** Tuesday, July 27, 2021 10:11 AM  
**To:** Smith, Michael (CBER) <[Michael.Smith2@fda.hhs.gov](mailto:Michael.Smith2@fda.hhs.gov)>; Aghajani Memar, Neda <[Neda.AghajaniMemar@pfizer.com](mailto:Neda.AghajaniMemar@pfizer.com)>; Devlin, Carmel M <[Carmel.Devlin@pfizer.com](mailto:Carmel.Devlin@pfizer.com)>  
**Cc:** Naik, Ramachandra <[Ramachandra.Naik@fda.hhs.gov](mailto:Ramachandra.Naik@fda.hhs.gov)>; Gottschalk, Laura <[Laura.Gottschalk@fda.hhs.gov](mailto:Laura.Gottschalk@fda.hhs.gov)>  
**Subject:** [EXTERNAL] RE: STN 125742.0: IR RE assessment of vaccine effectiveness

**CAUTION:** This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Mike,

I confirm receipt.

Best regards,

Elisa

**From:** Smith, Michael (CBER) <[Michael.Smith2@fda.hhs.gov](mailto:Michael.Smith2@fda.hhs.gov)>  
**Sent:** Tuesday, July 27, 2021 10:01 AM  
**To:** Harkins Tull, Elisa <[Elisa.HarkinsTull@pfizer.com](mailto:Elisa.HarkinsTull@pfizer.com)>; Aghajani Memar, Neda <[Neda.AghajaniMemar@pfizer.com](mailto:Neda.AghajaniMemar@pfizer.com)>; Devlin, Carmel M <[Carmel.Devlin@pfizer.com](mailto:Carmel.Devlin@pfizer.com)>  
**Cc:** Naik, Ramachandra <[Ramachandra.Naik@fda.hhs.gov](mailto:Ramachandra.Naik@fda.hhs.gov)>; Gottschalk, Laura <[Laura.Gottschalk@fda.hhs.gov](mailto:Laura.Gottschalk@fda.hhs.gov)>  
**Subject:** [EXTERNAL] STN 125742.0: IR RE assessment of vaccine effectiveness

Elisa,

The review team has the below Information Request for Pfizer and BioNTech Manufacturing GmbH.

1. Regarding the cumulative incidence rates, please calculate vaccine effectiveness with confidence intervals during the two intervals of interest separately from days 35-91 (i.e., 8 weeks of observation after dose 2) and from days 91-224 (more prolonged follow up post vaccination series).
2. We also request assessment of vaccine effectiveness during a time period that is entirely further out from vaccination (e.g., starting at 4 months post-dose 2). We acknowledge though that at some point unblinding and placebo cross-over started, and there may have been differential loss between the two groups from blinded follow-up that could introduce bias and/or confound the analyses.

Please respond within one week from today.

Regards,

Mike

- Please confirm receipt of this e-mail and let us know if you have any questions.

**Mike Smith, Ph.D.**  
**Captain, USPHS**

**Senior Regulatory Review Officer  
Food and Drug Administration  
Center for Biologics Evaluation & Research  
Office of Vaccines Research & Review  
Division of Vaccines and Related Products Applications**

Tel: 301-796-2640

[michael.smith2@fda.hhs.gov](mailto:michael.smith2@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.